Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 15, 2023 at 09:17 am
Share
Seoulin Bioscience Co.,Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 9.2 million compared to KRW 34.05 million a year ago. Net income was KRW 1,804.51 million compared to KRW 2,058.36 million a year ago.
Basic earnings per share from continuing operations was KRW 210.9542 compared to KRW 241.2301 a year ago. Diluted earnings per share from continuing operations was KRW 210.9542 compared to KRW 237.3235 a year ago. Basic earnings per share was KRW 210.9542 compared to KRW 240.2534 a year ago.
Diluted earnings per share was KRW 210.9542 compared to KRW 236.3469 a year ago.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
SEOULIN BIOSCIENCE CO.,LTD. 
